{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:11:19Z","timestamp":1793362279728,"version":"4.5.0"},"reference-count":69,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -methamphetamine (MDMA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Swiss PAT practices were examined using an anonymous survey of physicians providing PAT. Questions included physicians\u2019 backgrounds, training, therapeutic orientation, treatment protocols, patient characteristics, and perceived benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Participants were recruited from PAT professional associations and the research team network. Forty-one physicians providing PAT under FOPH exemptions contributed to the survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Respondents used PAT primarily for depression, anxiety, post-traumatic stress disorder (PTSD), and chronic pain. Most physicians practiced in private practices, private outpatient clinics or shared practices (82%), with a minority in hospitals (18%). The most reported labels when providing PAT were body-oriented (61%), psychodynamic (59%), and eclectic (54%) approaches. Respondents provided PAT using psilocybin (85%), MDMA (71%), and LSD (65.9%). Choice of first substance was linked to diagnosis, with physicians preferring psilocybin for depression (54%) and substance use disorder (46%) and MDMA for PTSD (86%) and anxiety disorders (54%). A total of 90% reported always playing music during psychedelic sessions. Loss of orientation in time and space, feeling too cold, anxiety, and nausea where the most frequent adverse effects of PAT. 95% had emergency medication available, on average used during 2.4% of sessions. Challenges included legal constraints, high patient expectations, and financial barriers. Group therapy was common, with 9% reporting providing only group sessions, 42% providing both individual and group settings, and 47% providing only individual sessions. Only 9% reported never using co-sitters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study offers valuable insights into the methods and experiences of physicians providing PAT in a legal clinical context, giving insight into the considerable variety of clinical methods. Cultural and regulatory differences may limit generalizability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253261448745","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:18:56Z","timestamp":1779272336000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0039-1302","authenticated-orcid":false,"given":"Kristian","family":"Beichmann","sequence":"first","affiliation":[{"name":"Molecular Psychiatry Laboratory, Faculty of Science and Medicine, University of Fribourg, Villars-sur-Gl\u00e2ne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-7790","authenticated-orcid":false,"given":"Polina","family":"Catzeflis","sequence":"additional","affiliation":[{"name":"Molecular Psychiatry Laboratory, Faculty of Science and Medicine, University of Fribourg, Villars-sur-Gl\u00e2ne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-7086","authenticated-orcid":false,"given":"Helena D.","family":"Aicher","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Substance-Assisted Therapy, Department of Psychiatry, Division of Medicine, University of Basel, Basel, Switzerland"},{"name":"Swiss Medical Association for Psychedelic Therapy (S\u00c4PT), Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-770X","authenticated-orcid":false,"given":"Federico","family":"Seragnoli","sequence":"additional","affiliation":[{"name":"Psychiatry Department, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Institute of Psychology, University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-404X","authenticated-orcid":false,"given":"Abigail","family":"Calder","sequence":"additional","affiliation":[{"name":"Molecular Psychiatry Lab, Faculty of Science and Medicine, University of Fribourg, Villars-sur-Gl\u00e2ne, Switzerland"},{"name":"Fribourg Mental Health Network, Villars-sur-Gl\u00e2ne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Amrani","sequence":"additional","affiliation":[{"name":"Molecular Psychiatry Laboratory, Faculty of Science and Medicine, University of Fribourg, Villars-sur-Gl\u00e2ne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8311-0138","authenticated-orcid":false,"given":"Gregor","family":"Hasler","sequence":"additional","affiliation":[{"name":"Molecular Psychiatry Laboratory, Faculty of Science and Medicine, University of Fribourg, Villars-sur-Gl\u00e2ne, Switzerland"},{"name":"Fribourg Mental Health Network, Chemin du Cardinal-Journet 3, Villars-sur-Gl\u00e2ne 1752, Switzerland"},{"name":"Lake Lucerne Institute, Vitznau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.05.019"},{"issue":"9","key":"e_1_3_4_3_2","article-title":"Psychedelic-assisted therapy for palliative care within a home treatment setting: a case report","volume":"12","author":"Seragnoli F","year":"2024","unstructured":"Seragnoli F, Martignoni G, Martignoni E, et al. Psychedelic-assisted therapy for palliative care within a home treatment setting: a case report. Clin Case Rep 2024; 12(9): e9305.","journal-title":"Clin Case Rep"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X241312604"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1513022"},{"key":"e_1_3_4_6_2","unstructured":"Chandimal NA. Regulatory amendments authorize requests for psychedelic restricted drugs: cassels https:\/\/cassels.com\/insights\/regulatory-amendments-authorize-requests-for-psychedelic-restricted-drugs\/#:~:text=As%20of%20January%205%2C%202022%2C 3 (2022 accessed 15 March 2025)."},{"key":"e_1_3_4_7_2","unstructured":"Lu D. Australian psychiatrists can now prescribe MDMA | psilocybin: who can access them and how do they work?. The Guardian. https:\/\/www.theguardian.com\/australia-news\/2023\/jul\/01\/australian-psychiatrists-can-now-prescribe-mdma-and-psilocybin-who-can-access-them-and-how-do-they-work#:~:text=From%20July%201%20psychiatrists%20in announced%20the%20change%20in%20February (2023). ."},{"key":"e_1_3_4_8_2","unstructured":"Kenney A. What to know about Colorado\u2019s psychedelic law. CPR News https:\/\/www.cpr.org\/2023\/06\/21\/colorado-psychedelic-law-for-psilocybin-mushrooms\/ (2023 accessed 27 February 2025)."},{"key":"e_1_3_4_9_2","unstructured":"Carboni LP. New Mexico Becomes Third State in the U.S. to Legalize Access to Psilocybin: Foley & Lardner LLP https:\/\/www.foley.com\/insights\/publications\/2025\/04\/new-mexico-becomes-third-state-us-legalize-access-psilocybin\/ (2025 accessed 20 April 2025)."},{"key":"e_1_3_4_10_2","unstructured":"Ginsberg NL. Israel embraces research on MDMA-assisted therapy for PTSD. Multidisciplinary Association for Psychedelic Studies (MAPS) https:\/\/maps.org\/2020\/02\/26\/press-release-israel-embraces-research-on-mdma-assisted-psychotherapy-for-ptsd\/#:~:text=On%20February%203%2C%202019%2C%20Israel Tel%20Hashomer (2020 accessed 27 February 2025)."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0007"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06620-x"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00489-1"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.737738"},{"key":"e_1_3_4_15_2","unstructured":"Gesundheit Bd. Limited medical use of banned narcotics 2025 https:\/\/www.bag.admin.ch\/bag\/en\/home\/gesetze-und-bewilligungen\/gesuche-bewilligungen\/ausnahmebewilligungen-bewilligungen-betmg\/ausnahmebewilligungen-verbotene-betaeubungsmittel\/ausnahmebewilligungen-beschraenkte-medizinische-anwendung.html (2025 accessed 07.02.2025)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00278-024-00711-y"},{"issue":"1","key":"e_1_3_4_17_2","first-page":"28","article-title":"Research update: psychedelic group therapy in Switzerland","volume":"27","author":"Gasser P.","year":"2017","unstructured":"Gasser P. Research update: psychedelic group therapy in Switzerland. MAPS Bulletin 2017; 27(1): 28\u201329.","journal-title":"MAPS Bulletin"},{"key":"e_1_3_4_18_2","first-page":"23","volume-title":"Disruptive psychopharmacology. Current topics in behavioral neurosciences","author":"Gasser P.","year":"2022","unstructured":"Gasser P. Psychedelic group therapy. In: Barrett FS, Preller KH (ed). Disruptive psychopharmacology. Current topics in behavioral neurosciences. Cham: Springer, 2022, pp. 23\u201334."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114555249"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120959604"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amp.2024.05.014"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2025.105525"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.1031"},{"key":"e_1_3_4_24_2","unstructured":"Aicher HD Duffour C Liechti ME et al. Treatment recommendations Psychedelic-assisted therapy (PAT): PAT Psychedelic-Assisted Therapy IG https:\/\/swisspsychedelic.ch\/wp-content\/uploads\/2024\/09\/Treatment_recommendations_PAT.pdf (2024 accessed 15 February 2025)."},{"key":"e_1_3_4_25_2","unstructured":"Benz E. Halluzinogen-unterst\u00fctzte Psychotherapie. Erhebung bei der Schweizerischen \u00c4rztegesellschaft f\u00fcr Psycholytische Therapie. [Doctoral]. Psychiatrische Universit\u00e4tsklinik Z\u00fcrich (Burgh\u00f6lzli) 1989."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"issue":"0","key":"e_1_3_4_27_2","first-page":"1","article-title":"Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: an interpretive phenomenological analysis","volume":"0","author":"Agin-Liebes G","year":"2021","unstructured":"Agin-Liebes G, Ekman E, Anderson B, et al. Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: an interpretive phenomenological analysis. J Humanistic Psychol 2021; 0(0): 1\u201328.","journal-title":"J Humanistic Psychol"},{"key":"e_1_3_4_28_2","volume-title":"Healing with entactogens: Therapist and patient perspectives on MDMA-assisted group psychotherapy","author":"Passie T.","year":"2012","unstructured":"Passie T. Healing with entactogens: Therapist and patient perspectives on MDMA-assisted group psychotherapy. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies (MAPS), 2012."},{"key":"e_1_3_4_29_2","first-page":"165","volume-title":"Therapie mit psychoaktiven Substanzen Praxis und Kritik der Psychotherapie mit LSD, Psilocybin und MDMA","author":"Passie T","year":"2008","unstructured":"Passie T, D\u00fcrst T. Heilungsprozesse im ver\u00e4nderten Bewusstsein: Elemente psycholytischer Therapieerfahrung aus der Sicht von Patienten. In: Jungarberle H, Gasser P, Weinhold J, et al. (eds). Therapie mit psychoaktiven Substanzen Praxis und Kritik der Psychotherapie mit LSD, Psilocybin und MDMA. Bern: Verlag Hans Huber, 2008, pp. 165\u2013194."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1020505"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00169"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00748-y"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.02.006"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10608-025-10588-z"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231155117"},{"key":"e_1_3_4_36_2","volume-title":"Theory and practice of group psychotherapy","author":"Yalom ID.","year":"1995","unstructured":"Yalom ID. Theory and practice of group psychotherapy. 5th ed. New York, NY, USA: Basic Books, 1995.","edition":"5"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20221043"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1505894"},{"key":"e_1_3_4_39_2","unstructured":"Team RC. R: a language and environment for statistical computing (Version 4.3.1). Computing RFfS 2023."},{"key":"e_1_3_4_40_2","unstructured":"Team R. RStudio: integrated development environment for R (Version 2024.09.1+394). Posit Software P 2024."},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.122993"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-022-01063-5"},{"key":"e_1_3_4_43_2","first-page":"3","volume-title":"Current topics in behavioral neurosciences","author":"Liechti ME","year":"2021","unstructured":"Liechti ME, Holze F. Dosing psychedelics and MDMA. In: Barrett FS and Preller KH (eds) Disruptive psychopharmacology. Current topics in behavioral neurosciences, vol. 56. Cham, Switzerland: Springer, 2021, pp. 3\u201321."},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.2546"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100725"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.10320"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12152-023-09536-z"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2019.1593559"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104793"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2018.009"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0054"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2022.0004"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2024.2357669"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.873279"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1177\/07067437231225937"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0033"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psychotherapy.20240025"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.58188\/2767-7176.1025"},{"key":"e_1_3_4_60_2","article-title":"Treatment recommendations for psychedelic-assisted therapy","volume":"175","author":"Aicher HD","year":"2024","unstructured":"Aicher HD, Gasser P. Treatment recommendations for psychedelic-assisted therapy. Swiss Archives Neurol Psychiatry Psychotherapy 2024; 175: 1488043038.","journal-title":"Swiss Archives Neurol Psychiatry Psychotherapy"},{"key":"e_1_3_4_61_2","first-page":"69","article-title":"Therapeutic guidelines: dangers and contra-indications in therapeutic applications of hallucinogens","volume":"1","author":"Frecska E.","year":"2007","unstructured":"Frecska E. Therapeutic guidelines: dangers and contra-indications in therapeutic applications of hallucinogens. Psychedelic Med 2007; 1: 69\u201396.","journal-title":"Psychedelic Med"},{"key":"e_1_3_4_62_2","article-title":"Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies","volume":"29","author":"Sab\u00e9 M","year":"2024","unstructured":"Sab\u00e9 M, Sulstarova A, Glangetas A, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry 2024; 29: 3139\u20133171.","journal-title":"Mol Psychiatry"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2025.06.003"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-025-06871-y"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.20240136"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/cku151.050"},{"key":"e_1_3_4_68_2","unstructured":"Association FSM. Statistique m\u00e9dicale de la FMH https:\/\/www.fmh.ch\/fr\/themes\/statistique-medicale\/statistique-medicale-fmh.cfm (2025 accessed 2 February 2025)."},{"key":"e_1_3_4_69_2","unstructured":"Association FSM. M\u00e9decins dans le secteur ambulatoire par discipline principale et par canton; 2024 https:\/\/www.fmh.ch\/files\/pdf32\/3.-medecins-dans-le-secteur-ambulatoire-par-discipline-principale-et-par-canton.pdf (2025 accessed 2 February 2025)."},{"key":"e_1_3_4_70_2","unstructured":"Association FSM. M\u00e9decins par discipline principale et par canton; 2024 https:\/\/www.fmh.ch\/files\/pdf32\/2.-medecins-en-exercice-par-discipline-principale-et-par-canton.pdf (2025 accessed 2 February 2025)."}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261448745","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253261448745","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261448745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T22:46:42Z","timestamp":1779576402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253261448745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":69,"alternative-id":["10.1177\/20451253261448745"],"URL":"https:\/\/doi.org\/10.1177\/20451253261448745","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"20451253261448745"}}